**Proportion of Participants with New Diagnosis of Diabetes or New Use of Medication for Diabetes through Week 96**

|  | Weight Gain Group | | | |
| --- | --- | --- | --- | --- |
|  | Low: <10% | | High: ≥10% | |
| Treatment Group | n | % (95% CI) | n | % (95% CI) |
| New Diagnosis of Diabetes | | | | |
| Doravirine | 579 | 1.2 (0.5, 2.5) | 97 | 1.0 (0.0, 5.6) |
| Darunavir | 225 | 1.8 (0.5, 4.5) | 43 | 0.0 (0.0, 8.2) |
| Efavirenz | 310 | 1.9 (0.7, 4.2) | 52 | 3.8 (0.5, 13.2) |
| New Use of Medication for Diabetes | | | | |
| Doravirine | 568 | 0.4 (0.0, 1.3) | 93 | 0.0 (0.0, 3.9) |
| Darunavir | 221 | 0.9 (0.1, 3.2) | 42 | 2.4 (0.2, 12.6) |
| Efavirenz | 306 | 0.7 (0.1, 2.3) | 52 | 0.0 (0.0, 6.8) |
| Subjects with missing weight change are not included in the analysis.  Subjects are considered as having the diagnosis for the condition for the visit if they had relevant adverse experiences starting in that visit and retained for the subsequent visits.  Use of medication of interest is based on subject’s concomitant medication data post baseline. Subjects are considered as having used the medication of interest in a visit if they did not use the medication at baseline but used the medication post baseline and the interval of use, from first use to last use, falls into the visit. Subjects who used the medications of interest before the study were excluded. | | | | |